Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 5:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Transarterial embolization Clear all
Terminated Not applicable Interventional Results available

LC Bead LUMI Radio-Opaque Embolic Beads to Detect and Characterize the Vascularity of Hepatic Tumors

NCT02649868
View directory record Official record
Conditions
Hepatic Cancer, Liver Neoplasms, Hepatocellular Cancer, Liver Cancer
Interventions
Transarterial embolization (TAE), LC Bead LUMI
Procedure · Device
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Sep 20, 2026, 5:36 PM EDT
Completed Phase 2 Interventional

Sorafenib Tosylate Before and After Hepatic Arterial Chemoembolization With Doxorubicin Hydrochloride and Mitomycin C in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery

NCT00949182
View directory record Official record
Conditions
Liver Cancer
Interventions
sorafenib tosylate, HACE : Doxorubicin Hydrochloride and Mitomycin C, laboratory biomarker analysis
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Sep 20, 2026, 5:36 PM EDT
Completed No phase listed Observational

Quality of Life in Patients Undergoing Embolization Using Yttrium Y 90 Glass Microspheres for Primary or Metastatic Liver Cancer

NCT00739167
View directory record Official record
Conditions
Liver Cancer, Metastatic Cancer
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Sep 20, 2026, 5:36 PM EDT
Recruiting Phase 1 Interventional

Achilles Tendinopathy Embolization

NCT07477860
View directory record Official record
Conditions
Achilles Tendinopathy (AT)
Interventions
LipioJoint
Device
Lead sponsor
Joint & Vascular Institute
Industry
Eligibility
25 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Libertyville, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 20, 2026, 5:36 PM EDT
Active, not recruiting Phase 2 Interventional

Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases

NCT04728633
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma, Stage IV Choroidal and Ciliary Body Melanoma AJCC V8
Interventions
Carmustine, Ethiodized Oil, Transarterial Chemoembolization, Medical Device Usage and Evaluation
Drug · Procedure · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 20, 2026, 5:36 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer

NCT04331717
View directory record Official record
Conditions
Prostate Adenocarcinoma, Obesity, Morbid
Interventions
Bead Block 300-500 um, Weight Management, Lupron
Device · Behavioral · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2022 · Synced Sep 20, 2026, 5:36 PM EDT
Completed Phase 2 Interventional

Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver

NCT02724540
View directory record Official record
Conditions
Neuroendocrine Tumor, Malignant, Liver Metastases
Interventions
Bland Embolization, Transarterial chemoembolization, Drug Eluting Beads Embolization
Device · Combination Product
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
10
States / cities
San Francisco, California • Standford, California • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2025 · Synced Sep 20, 2026, 5:36 PM EDT
Completed Phase 1 Interventional

Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer

NCT01042041
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Cancer, Localized Unresectable Liver Cancer
Interventions
sorafenib tosylate, doxorubicin hydrochloride, cisplatin, mitomycin C, transarterial chemoembolization, hepatic artery embolization
Drug · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 25, 2013 · Synced Sep 20, 2026, 5:36 PM EDT
Recruiting Not applicable Interventional

Embolization Treatment of Chronic Refractory Shoulder Tendinopathy

NCT06095050
View directory record Official record
Conditions
Shoulder Pain, Tendinopathy, Rotator Cuff Tendinitis, Rotator Cuff Tendinosis, Embolization, Arterial Occlusion
Interventions
Embolization, Physical Therapy
Device · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 20, 2026, 5:36 PM EDT
Withdrawn Phase 1 Interventional

Preoperative Embolization of Hypervascular Head and Neck Tumors to Improve Surgical Outcomes

NCT05490381
View directory record Official record
Conditions
Malignant Neoplasm in the Head and Neck, Metastatic Malignant Neoplasm in the Head and Neck
Interventions
Iodixanol, Angiogram, Arterial Embolization, Polyvinyl Alcohol, Ethiodized Oil, Computed Tomography, Chart Abstraction
Other · Procedure · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Sep 20, 2026, 5:36 PM EDT
Recruiting Phase 2 Interventional

Combination of TATE and PD-1 Inhibitor in Liver Cancer

NCT03259867
View directory record Official record
Conditions
Hepatocellular Carcinoma, Gastric Cancer
Interventions
Nivolumab Injectable Product, Trans-arterial tirapazamine embolization
Drug · Combination Product
Lead sponsor
Teclison Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
3
States / cities
Orange, California • Oklahoma City, Oklahoma • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 20, 2026, 5:36 PM EDT
Recruiting Phase 1Phase 2 Interventional

Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

NCT02174549
View directory record Official record
Conditions
Hepatocellular Carcinoma, Gastrointestinal Cancer Metastatic, Neuroendocrine Tumors
Interventions
Tirapazamine, Conventional Transarterial Embolization (TAE)
Drug · Procedure
Lead sponsor
Teclison Ltd.
Industry
Eligibility
20 Years to 99 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
2
States / cities
Palo Alto, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 20, 2026, 5:36 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells

NCT03107416
View directory record Official record
Conditions
Unresectable Hepatocellular Carcinoma
Interventions
Hepatic artery embolization (HAE), Bumetanide
Procedure · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 20, 2026, 5:36 PM EDT
Completed Not applicable Interventional Results available

Caterpillar™ Arterial Embolization Device Post-Market Study

NCT04244370
View directory record Official record
Conditions
Embolization, Therapeutic
Interventions
Caterpillar™ Arterial Embolization Device
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • Miami, Florida • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Sep 20, 2026, 5:36 PM EDT
Recruiting Not applicable Interventional

qDSA Blood Flow Measurement in Patients Undergoing TAE of the Liver

NCT06971991
View directory record Official record
Conditions
Transarterial Embolism, Transarterial Chemoembolization, Radioembolization
Interventions
qDSA Blood Flow Measurement
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 20, 2026, 5:36 PM EDT
Completed Phase 2 Interventional Results available

Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma

NCT04301778
View directory record Official record
Conditions
Unresectable Intrahepatic Cholangiocarcinoma
Interventions
Durvalumab, SNDX-6352
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 20, 2026, 5:36 PM EDT
Recruiting Not applicable Interventional

Embolization for the Treatment of Heel Pain Secondary to Plantar Fasciitis

NCT06805942
View directory record Official record
Conditions
Plantar Fasciitis of Both Feet
Interventions
Lipiodol (ethiodized oil) injection
Device
Lead sponsor
IR Centers
Other
Eligibility
22 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 20, 2026, 5:36 PM EDT
Not listed Phase 1Phase 2 Interventional

Embolization for the Treatment of Pain Secondary to Adhesive Capsulitis

NCT03676829
View directory record Official record
Conditions
Frozen Shoulder, Adhesive Capsulitis
Interventions
Arterial Embolization of the Shoulder
Device
Lead sponsor
Vascular Institute of Virginia
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Woodbridge, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Sep 20, 2026, 5:36 PM EDT
Enrolling by invitation No phase listed Observational

Case-Specific Health Care Professional Clinical Survey for Concerto Versa™ Detachable Coils

NCT07639853
View directory record Official record
Conditions
Arteriovenous Malformation, Gastrointestinal Bleed, Gastric Varices, Hemorrhoid, Pelvic Venous Disorders, Peripheral Aneurysms, Portal Vein Embolization, Type II Endoleak, Varicocele, Hemorrhage
Interventions
Concerto Versa™ Detachable Coils
Device
Lead sponsor
Medtronic Endovascular
Industry
Eligibility
22 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 20, 2026, 5:36 PM EDT
Recruiting Phase 1 Interventional

Lateral Plantar Artery Embolization For Plantar Fasciitis

NCT07395128
View directory record Official record
Conditions
Plantar Fasciitis, Chronic, Plantar Fasciitis
Interventions
Lipiodol
Device
Lead sponsor
Joint & Vascular Institute
Industry
Eligibility
25 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Libertyville, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 20, 2026, 5:36 PM EDT
Not listed Not applicable Interventional

Splenic Injury Embolization - the Question About NOM (SInE Qua NOM)

NCT03231202
View directory record Official record
Conditions
Wounds and Injuries
Interventions
Embolization
Procedure
Lead sponsor
Oslo University Hospital
Other
Eligibility
16 Years to 80 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Denver, Colorado • Pittsburgh, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Sep 20, 2026, 5:36 PM EDT
Recruiting Not applicable Interventional

Rectal Arterial Embolization vs Band Ligation for the Treatment of Internal hemOrrhoidS

NCT07559630
View directory record Official record
Conditions
Hemorrhoidal Bleeding, Hemorrhoids, Internal, HAE, RBL
Interventions
Hemorrhoidal Artery Embolization, Rubber Band Ligation
Device · Procedure
Lead sponsor
Jessica K. Stewart, MD
Other
Eligibility
18 Years to 89 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 20, 2026, 5:36 PM EDT
Completed Early Phase 1 Interventional

A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer

NCT03143270
View directory record Official record
Conditions
Liver Cancer
Interventions
Drug Eluting Bead Transarterial Chemoembolization, Nivolumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
9
States / cities
St Louis, Missouri • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 20, 2026, 5:36 PM EDT
Completed Not applicable Interventional Results available

Instylla HES Hypervascular Tumor Pivotal Study

NCT04523350
View directory record Official record
Conditions
Hypervascular Tumors
Interventions
Instylla HES, TAE or cTACE
Device · Other
Lead sponsor
Instylla, Inc.
Industry
Eligibility
22 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Irvine, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 20, 2026, 5:36 PM EDT